SIA
NTLA icon

Sit Investment Associates’s Intellia Therapeutics NTLA Stock Holding History

Sit Investment Associates’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-85,500
Closed -$608K – 538
2025
Q1 		$608K Hold
85,500
– – 0.01% 399
2024
Q4 		$997K Buy
85,500
+25,600
+43% +$400K 0.02% 380
2024
Q3 		$1.23M Hold
59,900
– – 0.03% 363
2024
Q2 		$1.34M Buy
59,900
+22,350
+60% +$532K 0.03% 340
2024
Q1 		$1.03M Buy
37,550
+3,100
+9% +$86.1K 0.02% 357
2023
Q4 		$1.05M Hold
34,450
– – 0.03% 354
2023
Q3 		$1.09M Hold
34,450
– – 0.03% 335
2023
Q2 		$1.41M Buy
34,450
+9,775
+40% +$396K 0.04% 326
2023
Q1 		$920K Buy
+24,675
New +$968K 0.03% 358

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sit Investment Associates's NTLA Position: Q2 2025 in Review

Sit Investment Associates sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 85,500 shares — an estimated $608K sold.

Sit Investment Associates first reported a position in NTLA in Q1 2023 and held it in 9 quarters. The position peaked at $1.41M in Q2 2023. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Sit Investment Associates reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sit Investment Associates sold 85,500 Intellia Therapeutics shares in Q2 2025, an estimated $608K.
  • Sit Investment Associates first reported a position in Intellia Therapeutics in Q1 2023 and held it in 9 quarters.
  • Sit Investment Associates's Intellia Therapeutics position peaked at $1.41M in Q2 2023.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Sit Investment Associates's 13F filing for Q2 2025, filed 14 Aug 2025.